Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RECLAIM: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer

NCT07419880 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07419880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07419880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RECLAIM: Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
June 30, 2028
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple -negative breast cancer